CGON Cost Of Revenue from 2010 to 2024
| CGON Stock | 34.75 0.65 1.91% |
Cost Of Revenue | First Reported 2010-12-31 | Previous Quarter 45.8 M | Current Value 48 M | Quarterly Volatility 16.5 M |
Check CG Oncology, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CG Oncology,'s main balance sheet or income statement drivers, such as Net Interest Income of 7.2 M, Depreciation And Amortization of 15.4 K or Interest Expense of 7.2 M, as well as many indicators such as Price To Sales Ratio of 750, Dividend Yield of 0.0 or PTB Ratio of 0.83. CGON financial statements analysis is a perfect complement when working with CG Oncology, Valuation or Volatility modules.
CGON |
Latest CG Oncology,'s Cost Of Revenue Growth Pattern
Below is the plot of the Cost Of Revenue of CG Oncology, Common over the last few years. Cost of Revenue is found on CG Oncology, Common income statement and represents the costs associated with goods and services CG Oncology, provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities. It is CG Oncology,'s Cost Of Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CG Oncology,'s overall financial position and show how it may be relating to other accounts over time.
| Cost Of Revenue | 10 Years Trend |
|
Cost Of Revenue |
| Timeline |
CGON Cost Of Revenue Regression Statistics
| Arithmetic Mean | 6,261,773 | |
| Geometric Mean | 31,711 | |
| Coefficient Of Variation | 263.55 | |
| Mean Deviation | 10,835,740 | |
| Median | 10,000 | |
| Standard Deviation | 16,503,037 | |
| Sample Variance | 272.4T | |
| Range | 48M | |
| R-Value | 0.59 | |
| Mean Square Error | 190.8T | |
| R-Squared | 0.35 | |
| Significance | 0.02 | |
| Slope | 2,181,015 | |
| Total Sum of Squares | 3812.9T |
CGON Cost Of Revenue History
About CG Oncology, Financial Statements
CG Oncology, investors utilize fundamental indicators, such as Cost Of Revenue, to predict how CGON Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Cost Of Revenue | 45.8 M | 48 M |
Pair Trading with CG Oncology,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CG Oncology, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CG Oncology, will appreciate offsetting losses from the drop in the long position's value.Moving against CGON Stock
| 0.45 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.43 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
| 0.39 | VTRS | Viatris | PairCorr |
| 0.32 | BFRIW | Biofrontera Warrants | PairCorr |
The ability to find closely correlated positions to CG Oncology, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CG Oncology, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CG Oncology, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CG Oncology, Common to buy it.
The correlation of CG Oncology, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CG Oncology, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CG Oncology, Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CG Oncology, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of CG Oncology, Correlation against competitors. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CG Oncology,. If investors know CGON will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CG Oncology, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (15.87) | Revenue Per Share 0.015 | Quarterly Revenue Growth 3.778 | Return On Assets (0.16) | Return On Equity (0.20) |
The market value of CG Oncology, Common is measured differently than its book value, which is the value of CGON that is recorded on the company's balance sheet. Investors also form their own opinion of CG Oncology,'s value that differs from its market value or its book value, called intrinsic value, which is CG Oncology,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CG Oncology,'s market value can be influenced by many factors that don't directly affect CG Oncology,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CG Oncology,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if CG Oncology, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CG Oncology,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.